Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patient-reported quality of life (QoL) was similar between ...

SAN FRANCISCO, September 29, 2025 — A new phase III clinical trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low ...

Please provide your email address to receive an email when new articles are posted on . Risk for late feeding tube dependence was low and did not differ between intensity-modulated radiation therapy ...

Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim ...

Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung cancer (NSCLC), as it reduces radiation exposure to the ...

NEW YORK (Reuters Health) - A new study of an intensive and expensive form of prostate cancer therapy finds that doctors who stand to profit from the treatment are twice as likely to recommend it, ...

The use of intensity-modulated proton therapy (IMPT) did not improve patient quality of life over the standard of care, intensity-modulated radiation therapy (IMRT), for the treatment of oropharyngeal ...

The use of intensity-modulated radiation therapy (IMRT) and the addition of gemcitabine to cisplatin increased the complete pathologic response (CPR) in women with locally advanced squamous cell ...

Treatment with a certain radiation therapy worsens quality of life in patients with prostate cancer. An expert explains ways to mitigate side effects. Patients with prostate cancer who receive ...

Proton beam therapy does not improve the patient-reported outcome of bowel function compared with IMRT. Bowel side effects do not differ between patients with localized prostate cancer who receive ...